Skip to main content
FDA OKs eculizumab for neuromyelitis optica spectrum disorder
7/15/2019

The FDA has approved Alexion Pharmaceuticals' Soliris, or eculizumab, an injectible for adults positive for the anti-aquaporin-4 antibody, as the first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease. Soliris is also approved for paroxysmal nocturnal hemoglobinuria and two other diseases.

Full Story: